Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: Phase III (AXIS) trial

British Journal of Cancer

Volumn 108, Issue 8, 2013, Pages 1571-1578

  Cella, D ^a   Escudier, B ^b   Rini, B ^c   Chen, C ^d   Bhattacharyya, H ^d   Tarazi, J ^d   Rosbrook, B ^d   Kim, S ^d   Motzer, R ^e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c TAUSSIG CANCER INSTITUTE   (United States)

^d PFIZER INC   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; SORAFENIB;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMIDAZOLES; INDAZOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; SELF REPORT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877010240     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.145     Document Type: Article

References (35)

1. Amir E, Seruga B, Kwong R, Tannock IF, Ocana A (2012) Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer Eur J Cancer 48: 385-388.
2. Beaumont JL, Butt Z, Baladi J, Motzer RJ, Haas T, Hollaender N, Kay A, Cella D (2011) Patient-reported outcomes in a phase III Study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy. Oncologist 16: 632-640.
3. Bukowski R, Cella D, Gondek K, Escudier B (2007) Effects of sorafenib on symptoms and quality of life: results from a large randomized placebocontrolled study in renal cancer. Am J Clin Oncol 30: 220-227.
4. Butt Z, Peipert J, Webster K, Chen C, Cella D (2012) General population norms for the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). Cancer 119: 429-437.
5. Cella D (2009) Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. Cancer Treat Rev 35: 733-737.
6. Cella D, Yount S, Brucker PS, Du H, Bukowski R, Vogelzang N, Bro WP (2007) Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health 10: 285-293.
7. Cella D, Yount S, Du H, Dhanda R, Gondek K, Langefeld K, George J, Bro WP, Kelly C, Bukowski R (2006) Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Support Oncol 4: 191-199.
8. Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R, Cihon F, Anderson S, Shah S, Bukowski R, Escudier B (2008) Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 100: 1454-1463.
9. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007a) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134.
10. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM (2009) Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27: 3312-3318.
11. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007b) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103-2111.
12. Fallowfield LJ, Fleissig A (2012) The value of progression-free survival to patients with advanced-stage cancer. Nat Rev 9: 41-47.
13. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C (2008) Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 34: 193-205.
14. Harding G, Cella D, Robinson Jr. D, Mahadevia PJ, Clark J, Revicki DA (2007) Symptom burden among patients with renal cell carcinoma (RCC): content for a symptom index. Health Qual Life Outcomes 5: 34.
15. Hedeker D, Gibbons R (2006) Longitudinal Data Analysisedn. John Wiley & Sons: Hoboken.
16. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27: 5794-5799.
17. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14: 7272-7283.
18. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281.
19. Kind P (1996) The EuroQol Instrument: An Index of Health-Related Quality of Life. Quality of Life and Pharmacoeconomics in Clinical Trials. In Spilker B (ed.) 2nd edn. Lippicott-Raven: Philadephia.
20. Lam JS, Belldegrun AS, Figlin RA (2004) Advances in immune-based therapies of renal cell carcinoma. Expert Rev Anticancer Ther 4: 1081-1096.
21. Linehan WM, Zbar B (2004) Focus on kidney cancer. Cancer Cell 6: 223-228.
22. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22: 454-463.
23. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116: 4256-4265.
24. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456.
25. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124.
26. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378: 1931-1939.
27. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP (2009) Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27: 4462-4468.
28. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI (2007) Axitinib treatment in patients with cytokine-refractory metastatic renalcell cancer: a phase II study. Lancet Oncol 8: 975-984.
29. Rubin D (1976) Inference and missing data. Biometrika 72: 359-364.
30. Singer J, Willett J (2003) Applied Longitudinal Data Analysis: Modeling Change and Event Occurrenceedn. Oxford University Press: New York.
31. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28: 1061-1068.
32. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
33. Trask PC, Bushmakin AG, Cappelleri JC, Bycott P, Liau K, Kim S (2008) Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib. Acta Oncol (Stockholm, Sweden) 47: 843-851.
34. Troxel AB, Fairclough DL, Curran D, Hahn EA (1998) Statistical analysis of quality of life with missing data in cancer clinical trials. Stat Med 17: 653-666.
35. Wagner LI, Wenzel L, Shaw E, Cella D (2007) Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions. J Clin Oncol 25: 5058-5062.